Drugs / CAM-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03414645 | May 2018 → Dec 2019 | asthenopia, dry eye syndrome, graft versus host disease | Cambium Bio Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06903611 | Oct 2026 → Nov 2027 expected | dry eye syndrome | Cambium Bio Limited | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAM-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06903611 ↗ |
| Route | Topical | “non-preserved topical ocular drop formulation” NCT03414645 ↗ |